Important Alert: Investors Warned About Corcept Therapeutics Lawsuit Post FDA Rejection
Corcept Investors Face Class Action Following FDA Rejection
Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) have recently been advised of an impending securities class action lawsuit after the company faced significant setbacks from the FDA. Led by the law firm Hagens Berman, the alert serves as a crucial reminder that the deadline for potential plaintiffs to take action is rapidly approaching on April 21, 2026.
Background of the Case
The class action lawsuit, titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., claims that Corcept management failed to disclose critical FDA warnings regarding their lead drug candidate, relacorilant, during crucial pre-submission meetings held in late 2024 and early 2025. Investors are encouraged to examine the details of the case available on Hagens Berman's CORT case page.
According to Reed Kathrein, a partner at Hagens Berman, the situation exemplifies a classic case of
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.